# Divergent Inflammatory Profiles but No Predictive Biomarkers of Psychiatric Sequelae After Viral Infection: A 12-Month Cohort Study

**Authors:** Piotr Lorkiewicz, Justyna Adamczuk, Justyna Kryńska, Mateusz Maciejczyk, Małgorzata Żendzian-Piotrowska, Robert Flisiak, Anna Moniuszko-Malinowska, Napoleon Waszkiewicz

PMC · DOI: 10.3390/ijms27041670 · International Journal of Molecular Sciences · 2026-02-09

## TL;DR

This study found that viral infections like SARS-CoV-2, HCV, and TBEV are linked to varied immune responses but not to specific psychiatric outcomes, suggesting complex factors are at play.

## Contribution

The study identifies divergent inflammatory profiles among viral infections but finds no predictive cytokine biomarkers for psychiatric sequelae.

## Key findings

- No significant differences in psychiatric outcomes were found between viral infection groups.
- Cytokines like IL-1β, TNF-α, and IL-10 showed inconsistent associations with symptoms.
- Two distinct inflammatory profiles were identified but did not predict clinical outcomes.

## Abstract

Viral infections have been implicated in psychiatric outcomes through immune-mediated pathways. This 12-month prospective cohort study, designed as a pilot and hypothesis-generating investigation, compared psychiatric symptoms and inflammatory cytokine profiles in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis C virus (HCV), and tick-borne encephalitis virus (TBEV), and explored their potential predictive value. Thirty-seven patients hospitalized with viral infections and 32 healthy controls were evaluated, acknowledging the limited sample size. Psychiatric interviews and the Hospital Anxiety and Depression Scale (HADS) were used for assessment. The study was divided into two stages. In Stage 1, during the acute infection, a psychiatric assessment was conducted, and cytokine levels were measured in the patients’ blood. In Stage 2, one year later, the psychiatric assessment was repeated. No significant differences were found in psychiatric diagnosis rates or symptom severity between infection groups, regardless of viral type or neuroinvasive capacity. However, these findings should be interpreted as preliminary given the limited sample size. Some cytokines, eg., interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and soluble interleukin-2 receptor subunit alpha (sIL-2Rα), showed associations with individual symptoms, but these were inconsistent and did not demonstrate robust predictive value. Cluster analysis identified two distinct inflammatory profiles—one characterized by higher cytokine levels (predominantly in Coronavirus disease 2019 (COVID-19) and TBEV cases) and the other by lower cytokine levels (mostly in HCV and controls). However, different cytokine profiles did not correspond to clinical outcomes. The results suggest that psychiatric sequelae after viral infections are not directly driven by specific cytokines or infection type but rather emerge from a complex interaction of immune, psychological, and environmental factors. Single cytokine measurement is insufficient and cannot be used as a tool for assessing the risk of developing psychiatric disorders. Given the exploratory nature of the study, all results require confirmation in larger, adequately powered cohorts. Future studies should focus on composite biomarkers and systems-based models such as neuroimmune-metabolic-oxidative pathways (NIMETOX), or Immune-Inflammatory Response System (IRS)/Compensatory Immune Response System (CIRS)/Oxidative & Nitrosative Stress (O&NS) for improved predictive accuracy.

## Linked entities

- **Proteins:** IL10 (interleukin 10)
- **Diseases:** severe acute respiratory syndrome coronavirus 2 (MONDO:0100096), Coronavirus disease 2019 (MONDO:0100096)

## Full-text entities

- **Genes:** CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, CSF3 (colony stimulating factor 3) [NCBI Gene 1440] {aka C17orf33, CSF3OS, GCSF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, LTA (lymphotoxin alpha) [NCBI Gene 4049] {aka LT, TNFB, TNFSF1, TNLG1E}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, IL9 (interleukin 9) [NCBI Gene 3578] {aka HP40, IL-9, P40}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, UBASH3B (ubiquitin associated and SH3 domain containing B) [NCBI Gene 84959] {aka STS-1, STS1, TULA-2, TULA2, p70}, RAF1 (Raf-1 proto-oncogene, serine/threonine kinase) [NCBI Gene 5894] {aka CMD1NN, CRAF, NS5, Raf-1, c-Raf}, IFNA2 (interferon alpha 2) [NCBI Gene 3440] {aka IFN-alpha-2, IFN-alphaA, IFNA, IFNA2B, leIF A}, TNFRSF1B (TNF receptor superfamily member 1B) [NCBI Gene 7133] {aka CD120b, TBPII, TNF-R-II, TNF-R75, TNFBR, TNFR1B}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}
- **Diseases:** neurotoxic (MESH:D020258), substance use disorder (MESH:D019966), Psychiatric Sequelae (MESH:D001523), Alzheimer's disease (MESH:D000544), cancer (MESH:D009369), Dysbiosis (MESH:D064806), Anxiety (MESH:D001007), neuroinflammation (MESH:D000090862), schizophrenia (MESH:D012559), asthma (MESH:D001249), CNS damage (MESH:D002493), meningitis (MESH:D008580), CNS inflammation (MESH:D007249), headache (MESH:D006261), injury to (MESH:D014947), neurodegeneration (MESH:D019636), metabolic disturbances (MESH:D024821), hyperlipidemia (MESH:D006949), cirrhosis (MESH:D005355), systemic illness (MESH:D012140), flu (MESH:D007251), sleep disturbances (MESH:D012893), chronic fatigue syndrome (MESH:D015673), MDD (MESH:D003865), PTSD (MESH:D013313), fever (MESH:D005334), ARDS (MESH:D012128), SLE (MESH:D008180), anxiety disorders (MESH:D001008), vomiting (MESH:D014839), hypoxia (MESH:D000860), mood disorders (MESH:D019964), respiratory failure (MESH:D012131), nausea (MESH:D009325), organ failure (MESH:D009102), autoimmune disease (MESH:D001327), delirium (MESH:D003693), O&amp;NS (MESH:D056770), neuropsychiatric manifestations (MESH:D012877), fatigue (MESH:D005221), COPD (MESH:D029424), pneumonia (MESH:D011014), energy loss (MESH:D011502), cardiovascular disease (MESH:D002318), infected (MESH:D007239), encephalitis (MESH:D004660), ischemic stroke (MESH:D002544), executive function deficits (MESH:D001289), psychosis (MESH:D011618), immunological disturbances (MESH:D007154), COVID-19 Infection (MESH:D000086382), toxicity (MESH:D064420), pareses (MESH:D010291), Chronic infection (MESH:D000088562), HCV infection (MESH:D006526), death (MESH:D003643), impaired consciousness (MESH:D003244), Viral Infection (MESH:D014777), tremor (MESH:D014202), hepatocellular carcinoma (MESH:D006528)
- **Chemicals:** cortisol (MESH:D006854), GABA (MESH:D005680), NE (MESH:D009638), Glu (MESH:D018698), kynurenine (MESH:D007737), quinolinic acid (MESH:D017378), psychoactive substances (-), DA (MESH:D004298), 5-HT (MESH:D012701), reactive oxygen species (MESH:D017382)
- **Species:** HCV [taxon 11103], Nicotiana tabacum (American tobacco, species) [taxon 4097], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376], Homo sapiens (human, species) [taxon 9606], Viruses (acellular root) [taxon 10239], Human immunodeficiency virus (species) [taxon 12721], Flaviviridae (family) [taxon 11050], Tick-borne encephalitis virus (no rank) [taxon 11084]
- **Mutations:** S18F, S18A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940611/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940611/full.md

## References

113 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940611/full.md

---
Source: https://tomesphere.com/paper/PMC12940611